New drug duo shows promise against tough cancers

NCT ID NCT05027139

Completed Disease control Sponsor: Jazz Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 02, 2026 · Updated 3 times

Summary

This study tested whether two drugs, zanidatamab and evorpacept, are safe and can shrink tumors in people with advanced HER2-expressing cancers. Fifty-two patients with breast or other cancers that had spread or couldn't be removed by surgery took part. The goal was to see how many patients responded and to check for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: zanidatamab and evorpacept (drugs given intravenously)
What this could lead to: If this combination works, it could offer a new treatment option for people with advanced HER2-expressing cancers that are hard to treat.
What could go wrong: This is an early-phase trial with only 52 participants, so results may not apply to everyone. Side effects are possible, and the combination may not shrink tumors in all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2-EXPRESSING CANCERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastroesophageal adenocarcinoma HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HER2-EXPRESSING CANCERS

Contacts and locations

Locations

Astera Cancer Care

East Brunswick, New Jersey, 08816, United States
Florida Cancer Specialists

Sarasota, Florida, 34232, United States
Magee-Womens Hospital of UPMC

Pittsburgh, Pennsylvania, 15213, United States
Northwest Medical Specialties, PLLC

Tacoma, Washington, 98405, United States
The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States
UC Irvine Health - Chao Family Comprehensive Cancer Center

Orange, California, 92868, United States
UC San Diego - Moores Cancer Center

La Jolla, California, 92093, United States
UCLA Department of Medicine Hematology/Oncology

Los Angeles, California, 90095, United States
University Hospitals Cleveland Medical Center

Cleveland, Ohio, 44106, United States
University of Vermont Medical Center

Burlington, Vermont, 05401, United States
University of Wisconsin - Madison

Madison, Wisconsin, 53792, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.